This 3rd generation construct, called DRhQ, was no longer DR2 restricted, had reduced effects on MOG-35-55 specific T cells, but retained the ability to block MIF effects in a number of different inflammatory conditions (stroke, methamphetamine abuse, and TBI) (Benedek et al., 2017; Yang et al., 2017; Meza-Romero et al., 2019; Vandenbark et al., 2019) in different mouse and rat strains without MHC restriction. The gene discussed is MOG; the disease is Stroke.